— Adds Portfolio of Branded Products with $48.9 million in 2025 Net Sales and an Established Commercial Presence —
— SYMPAZAN® Establishes a Neurology Rare Disease Footprint within Cosette —
— Additional Brands include INDOCIN®, SPRIX®, ZIPSOR®, CAMBIA®, and OTREXUP® —
Cosette Pharmaceuticals, Inc., a U.S.-based, branded specialty pharmaceutical company, announced today the closing of a definitive agreement to acquire the U.S. sales and distribution rights for a portfolio of seven branded products from Assertio Holdings, Inc. (Nasdaq: ASRT). The acquisition expands Cosette’s branded portfolio and adds the U.S. rights to SYMPAZAN®, a growing, patent-protected asset, further advancing Cosette’s disciplined growth strategy.
SYMPAZAN® (clobazam) oral film is an FDA-approved medicine for the adjunctive treatment of seizures associated with Lennox‐Gastaut Syndrome (LGS), a rare and severe form of epilepsy, in patients 2 years of age or older. SYMPAZAN® is a growing product with patent protection extending until 2040. As the first and only FDA-approved oral film formulation of clobazam, SYMPAZAN® addresses an important unmet need for LGS patients and establishes a Neurology rare disease footprint within Cosette’s branded portfolio.
“This acquisition reflects Cosette’s strategic approach to expanding our branded portfolio,” said Apurva Saraf, President and CEO of Cosette Pharmaceuticals. “It adds immediate scale through branded, on-market products and includes SYMPAZAN®, a growing, patent-protected asset in an orphan indication. Just as important, it reinforces our ability to execute strategic transactions propelling our growth. We look forward to successfully integrating these important medicines into Cosette and continuing to make them available for patients and prescribers.”
In addition to SYMPAZAN®, Cosette has acquired the rights to a portfolio that includes Assertio’s branded non-steroidal anti-inflammatory drugs (NSAIDs) treating indications in inflammation, pain management, and migraine:
- INDOCIN® (indomethacin), oral suspension
- INDOCIN® (indomethacin), suppositories
- SPRIX® (ketorolac tromethamine), nasal spray
- ZIPSOR® (diclofenac potassium), liquid-filled capsules
- CAMBIA® (diclofenac potassium), for oral solution
- OTREXUP® (methotrexate), injection for subcutaneous use
The agreement includes a transition period during which Assertio and Cosette will transfer responsibilities for the manufacture, supply, and commercialization of these products, including quality assurance, pharmacovigilance, and regulatory matters.
Products:
Please see Package Insert (PI) for full prescribing information including complete safety information:
- SYMPAZAN® (clobazam) oral film: See full prescribing information for important safety information, including Boxed Warning.
- INDOCIN® (indomethacin) oral suspension: See full prescribing information for important safety information, including Boxed Warning.
- INDOCIN® (indomethacin) suppositories: See full prescribing information for important safety information, including Boxed Warning.
- SPRIX® (ketorolac tromethamine) nasal spray: See full prescribing information for important safety information, including Boxed Warning.
- ZIPSOR® (diclofenac potassium) liquid-filled capsules: See full prescribing information for important safety information, including Boxed Warning.
- CAMBIA® (diclofenac potassium), for oral solution: See full prescribing information for important safety information, including Boxed Warning.
- OTREXUP® (methotrexate) injection for subcutaneous use: OTREXUP® was discontinued by Assertio in August 2025.
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
